Propanc Biopharma plans Phase 1b first-in-human PRP trial in advanced solid tumors starting February 2027
PPCB•Planned first-in-human Phase 1b study
Propanc Biopharma outlined plans to start a first-in-human Phase 1b study of PRP in February 2027.
The planned trial targets advanced solid tumors, with an initial focus on pancreatic cancer, ovarian cancer, and refractory prostate cancer.
PRP has not reported human efficacy results yet; the update centers on preclinical findings and a clinical-development timeline.
Management framed PRP as a potential add-on or maintenance approach alongside emerging RAS inhibitors to improve durability of responses.
